Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine

Methodist J.C. Walter Jr. Transplant Center - Houston, TX

Dr. Guillermo Torre-Amione

Total: 21 Projects

  1. EVALUATION OF THE EFFECT OF NEUROSTIMULATIO IN PATIENTS WITH SYMPTOMATIC HEART FAILURE; (2008) TORRE- PI (100%) 

  2. CRYOFILTRATION Clinical Evaluation of Membrane Plasma Exchange With Re-Infusion Of Purified Autologous Plasma For Treatment of Non-Ischemic Cardiomyopathy (Nine Patient Pilot Study) (2008) TORRE- PI (100%) 

  3. 503 TRIAL-Hemodynamic Effects of Rolofylline in the Treatment of Patients with Heart Failure A multicenter, Randomized, Double-blind, Placebo-controlled Study of the Hemodynamic Effects of Rolofylline Injectable Emulsion in the Treatment of Patients with Heart Failure.  (2008) TORRE- PI (100%)   

  4. CHAMPION-HF TORRE PI CHAMPION: CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients (Protocol CM-06-04) (2008) Torre G

  5. BALANCE TRIAL - PI  THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation(Protocol Number: CK-LX3401)   (2008) Torre G

  6. BIOGEN TRIAL - PI A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Effects of Intravenous BG9928 on Body Weight in Subjects with Acute Decompensated Heart Failure and Renal Insufficiency (2008) Torre G

  7. DOSE TRIAL - PI Diuretic Optimization Strategies Evaluation in Acute Heart Failure: The DOSE-AHF Study (Amendment 1 Version 19 – February 4, 2008) (2008) Torre G

  8. CARESS TRIAL -PI Protocol for the CARdiorenal REScue Study in Acute Decompensated Heart Failure (CARRESS HF) Version 2.0: April 11, 2008, Amendment 1  (2008) Torre G

  9. LEFT VENTRICULAR ASSIST DEVICE (LVAD) WORKING GROUP RECOVERY PROTOCOL (INTERNAL FUNDING)  (2001-PRESENT)  (DATABASE TISSUE) TORRE-PI (100%)

  10. WARFARIN VERSUS ASPIRIN IN REDUCED EJECTION FRACTION (WARCEF) National Institute of Neurological Disorders and Stroke, - (2002-PRESENT) (DRUG) TORRE-PI (100%)

  11. EVALUATION OF CELLULAR CHANGES INDUCED BY CARDIAC RE-SYNCHRONIZATION THERAPY IN PATIENTS WITH CONGESTIVE HEART FAILURE (Medtronic, Inc)  (2003-PRESENT) (DEVICE) TORRE-PI (100%)

  12. EVALUATION OF CELLULAR CHANGES INDUCED BY CARDIAC RE-SYNCHRONIZATION THERAPY IN PATIENTS WITH CONGESTIVE HEART FAILURE] (DEVICE) (2003-PRESENT) (Medtronic, Inc) TORRE-PI (100%)

  13. EFFECT OF IMMUNE MODULATION THERAPY (CELACADE (TM) ON LEFT VENTRICULAR SYSTOLIC AND DIASTOLIC FUNCTION SUBSTUDY PROTOCOL NO. 020202 AN ECHOCARDIOGRAPHIC SUBSTUDY OF THE ACCLAIM PROTOCOL: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF IMMUNE MODULATION THERAPY (IMT) ON MORTALITY AND MORBIDITY IN PATIENTS WITH CHRONIC HEART FAILURE [PROTOCOL NO. 0202] (AMENDMENT 2 DATED SEPTEMBER 28, 2004) (VASOGEN) (2003-PRESENT)  (DEVICE) TORRE-PI (100%)

  14. REGISTRY OF CARDIAC RESYNCHRONIZATION THERAPY-US (RESTORE-US) (MEDTRONIC) 2003-PRESENT  (DATABASE) TORRE-PI (100%)

  15. EFFECT OF PLASMA EXCHANGE ON PATIENTS WITH CHRONIC REFRACTORY HEART FAILURE  (2003-PRESENT) THE CAMPBELL FOUNDATION  (PROCEDURE) TORRE-PI (100%)

  16. PREDICTORS OF IN-HOSPTIAL MORTALITY IN PATIENTS WITH CONGESTIVE HEART FAILURE INTERNAL FUNDING - (2004-PRESENT)  (CHART REVIEW) TORRE-CO- PI (50%)

  17. GENETIC INFLUENCES ON LV RECOVERY RECENT ONSET CARDIOMYOPATHY (IMAC-II) (NIH) (2004-PRESENT) TORRE-PI (100%)

  18. TILARGININE ACETATE INJECTION IN A RANDOMIZED INTERNATIONAL STUDY IN UNSTABLE AMI PATIENTS/CARDIOGENIC SHOCK (TRIUMPH) ARG- CS3-001 (Arginox Pharmaceuticals, Inc.) (2005-PRESENT) (DRUG)TORRE-CO- PI (50%)

  19. FOLLOW-UP SERIAL INFUSIONS OF NATRECOR (NESIRITIDE) FOR THE MANAGEMENT OF PATIENTS WITH HEART FAILURE " FUSION II A034-B " ECHOCARDIOGRAPHY SUBSTUDY (SCIOS, INC.) (2005-PRESENT) (DRUG) TORRE-PI (100%)

  20. FOLLOW-UP SERIAL INFUSIONS OF NATRECOR(R) (NESIRITIDE) FOR THE MANAGEMENT OF PATIENTS WITH HEART FAILURE - FUSION II (#H16982) (SUBSTUDY - A034-C- PERIPHERAL COLLAGEN MARKER SUBSTUDY (SCIOS, INC.) (2005-PRESENT) (DRUG) TORRE-PI (100%)

  21. FOLLOW-UP SERIAL INFUSIONS OF NATRECOR(R) (NESIRITIDE) FOR THE MANAGEMENT OF PATIENTS WITH HEART FAILURE - FUSION II (#H16982) (FUSION II RENAL AND NEUROHORMONE SUBSTUDY (SCIOS, INC.) (2005-PRESENT) (DRUG) TORRE-PI (100%)